Mefloquine induces dose-related neurological effects in a rat model

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 3, 2006, Pages 1045-1053

  Dow, G ^a   Bauman, R ^a   Caridha, D ^a   Cabezas, M ^a   Du, F ^b   Gomez Lobo, R ^a   Park, M ^a   Smith, K ^a   Cannard, K ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b FD Neuro Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; MEFLOQUINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HISTOPATHOLOGY; MALARIA; NEUROLOGIC DISEASE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIMALARIALS; BRAIN STEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MEFLOQUINE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33644655507     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.3.1045-1053.2006     Document Type: Article

References (46)

1. Barret, P. J., P. D. Emmins, P. D. Clarke, and D. J. Bradley. 1996. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ 313:525-528.
2. Center for Drug Evaluation and Research. 2005. Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. [Online.] http://www.fda.gov/cder/guidance/5541fnl.htm. U.S. Food and Drug Administration, Washington, D.C.
3. Centers for Disease Control and Prevention. 2005. Treatment of malaria. [Online.] http://www.cdc.gov/malaria/diagnosis_treatment/clinicians2.htm. Centers for Disease Control and Prevention, Atlanta, Ga.
4. Centers for Disease Control and Prevention. 2005. Prescription drugs for preventing malaria. [Online.] http://www.cdc.gov/travel/malariadrugs.htm. Centers for Disease Control and Prevention, Atlanta, Ga.
5. Croft, A. M., and P. Garner. 2000. Mefloquine for preventing malaria in non-immune adult travelers. Cochrane Database Syst. Rev. 4:CD000138.
6. Cruikshank, S. J., M. Hopperstad, M. Younger, B. W. Connors, D. C. Spray, and M. Srinivas. 2004. Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc. Natl. Acad. Sci. USA 101:12364-12369.
7. Dietrich, M. 2004. Dizziness. Neurologist 10:154-164.
8. Dow, G. S., T. H. Hudson, M. Vahey, and M. L. Koenig. 2003. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malar. J. 2:14.
9. Fernaud-Espinosa, I., M. Nieto-Sampedro, and P. Bovolenta. 1993. Differential activation of microglia and astrocytes in aniso- and isomorphic gliotic tissue. Glia 8:277-291.
10. Finney, M. 1971. Probit analysis, 3rd ed. Cambridge University Press, Cambridge, United Kingdom.
11. Frankenfeld, C. 2004. "Serious" and "severe" adverse drug reactions need defining. BMJ 329:573.
12. Gallyas, F., L. Zaborszky, and J. R. Wolff. 1980. Experimental studies of mechanisms involved in methods demonstrating axonal and terminal degeneration. Stain Technol. 55:281-290.
13. Gallyas, F., G. Zoltay, and W. Dames. 1992. Formation of "dark" (argyrophilic) neurons of various origin proceeds with a common mechanism of biophysical nature (a novel hypothesis). Acta Neuropathol. 83:504-509.
14. Genovese, R. F., D. B. Newman, K. A. Gordon, and T. G. Brewer. 1999. Acute high dose arteether toxicity in rats. Neurotoxicology 20:851-860.
15. Genovese, R. F., D. B. Newman, and T. G. Brewer. 2000. Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol. Biochem. Behav. 67:37-44.
16. 2+ uptake by crude microsomes of rabbit skeletal muscle. Arch. Int. Pharmacodyn. Ther. 329:255-271.
17. Gribble, F. M., T. M. Davis, C. E. Higham, A. Clark, and F. M. Ashcroft. 2000. The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. Br. J. Pharmacol. 131:756-760.
18. Hellgren, U., I. Berggren-Palme, Y. Bervist, and M. Jerling. 1997. Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. Br. J. Clin. Pharmacol. 44:119-124.
19. Kollaritsch, H., J. Karbwang, G. Weiderman, A. Mikolasek, K. NaBangchang, and W. Wernsdorfer. 2000. Mefloquine concentration profiles during prophylactic drug regimens. Wien. Klin. Wochenschr. 112:441-447.
20. Lee, C., L. D. Kintner, T. R. Castles, A. M. Landes, M. C. Cronin, R. Hutchcraft, and F. Merle. 1972. Acute and subacute toxidties of α-(2piperidyl)-2,8-bis(trifluoromethyl)-4-quinolinemethanol hydrochloride, WR-142490 (AY-65742), in rodents. Interim report for USAMRDC contract no. DA-49-193-MD-2759. (Available upon request.)
21. Lim, L. Y., and M. L. Go. 1985. The anticholinesterase activity of mefloquine. Clin. Exp. Pharmacol. Physiol. 12:527-531.
22. Lu, L., F. Leonessa, M. T. Baynham, R. Clarke, F. Gimenez, Y. T. Pham, F. Roux, and I. W. Wainer. 2001. The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase. Pharm. Res. 18:1327-1330.
23. Lyeth, B. G., J. Y. Jiang, Q. X. Gong, R. J. Hamm, and H. F. Young. 1995. Effects of mu opioid agonist and antagonist on neurological outcome following traumatic brain injury in the rat. Neuropeptides 29:11-19.
24. Maertens, C., L. Wei, G. Droogmans, and B. Nilius. 2000. Inhibition of volume-regulated and calcium-activated chloride channels by the antimalarial mefloquine. J. Pharmacol. Exp. Ther. 295:29-36.
25. McDaniel, K. L., and V. C. Moser. 1993. Utility of a neurobehavioral screening battery for differentiating the effects of two pyrethroids, permethrin and cypermethrin. Neurotoxicol. Teratol. 15:71-83.
26. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
27. Nauta, W. J. H., and P. A. Gygax. 1954. Silver impregnation of degenerating axons in the central nervous system: a modified technique. Stain Technol. 29:91-93.
28. Ogeng'o, J. A., D. L. Cohen, J. G. Say, W. B. Matuja, H. M. Chande, J. N. Kitinya, J. K. Kimani, R. P. Friedland, H. Mon, and R. N. Kalaria. 1996. Cerebral amyloid beta protein deposits and other Alzheimer lesions in non-demented elderly East Africans. Brain Pathol. 6:101-108.
29. Paxinos, G., and C. Watson. 1986. The rat brain in stereotaxic coordinates. Academic Press, New York, N.Y.
30. Pham, Y.-T., A. Régina, R. Farinotti, P.-O. Couraud, I. W. Wainer, F. Roux, and F. Gimenez. 2000. Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalized rat brain capillary endothelial cell line, GPNT. Biochim. Biophys. Acta 1524:212-219.
31. Phillips-Howard, P. A., and F. O. ter Kuile. 1995. CNS adverse events associated with antimalarial agents: fact or fiction? Drug Saf. 12:370-383.
32. Price, R., J. A. Simpson, P. Teja-Isavatharm, M. M. Than, C. Luxemburger, D. G. Heppner, T. Chongsuphajaisiddhi, F. Nosten, and N. J. White. 1999. Pharmacokinetics of mefloquine combined with artcsunate in children with acute falciparum malaria. Antimicrob. Agents Chemother. 43:341-346.
33. Rendi-Wagner, P., H. Noedl, W. H. Wernsdorfer, G. Weidermann, A. Mikolasek, and H. Kollaritsch. 2002. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop. 81:167-173.
34. Roche Pharmaceuticals. 2005. Lariam product information. [Online.] http: //www.rocheusa.com/products/lariam/pi.pdf. Roche Pharmaceuticals, Nutley, N.J.
35. Ronn, A. M., J. Ronne-Rasmussen, P. C. Gotzsche, and I. C. Bygbjerg. 1998. Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and prospective study. Trop. Med. Int. Health 3:83-88.
36. Schlagenhauf, P., R. Steffen, H. Lobel, R. Johnson, R. Letz, A. Tschopp, Y. Bergqvist, O. Ericsson, U. Hellgren, L. Rombo, S. Mannino, J. Handschin, and D. Sturchler. 1996. Mefloquine tolerability during chemoprophylaxis: focus on adverse assessments, stereochemistry and compliance. Trop. Med. Int. Health 4:485-494.
37. Shah, S., S. Filler, L. M. Causer, A. K. Rowe, P. B. Bloland, A. M. Barber, J. M. Roberts, M. R. Desai, M. E. Parise, and R. W. Steketee. 2004. Malaria surveillance-United States, 2002. Morb. Mortal. Wkly. Rep. 53:21-36.
38. Shepherd, J., et al. September 1988. Use of (+) mefloquine for the treatment of malaria. International patent number WO 98/39003.
39. Simpson, J. A., R. Porce, F. ter Kuile, P. Teja-Isavatharm, F. Nosten, T. Chongsuphajaisiddhi, S. Looareesuwan, L. Aarons, and N. J. White. 1999. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin. Pharmacol. Ther. 66:472-484.
40. Tracy, D. J., and P. M. E. White. 1995. The sensosomatory system, p. 689-704. In G. Paxinos (ed.), The rat nervous system. Academic Press, San Diego, Calif.
41. Tung, A., S. Herrera, M. J. Szafran, K. Kasza, and W. B. Mendelson. 2005. Effect of sleep deprivation on righting reflex in the rat is partially reversed by administration of adenosine A1 and A2 receptor antagonists. Anesthesiology 102:1158-1164.
42. Urade, Y., N. Eguchi, W. M. Qu, M. Sakata, Z. L. Huang, J. F. Chen, M. A. Schwarzschild, J. S. Fink, and O. Hayaishi. 2003. Sleep regulation in adenosine A2A receptor-deficient mice. Neurology 61:S94-S96.
43. U.S. Environmental Protection Agency. 1998. Health effects test guidelines: OPPTS 870.6200 neurological screening battery. U.S. Environmental Protection Agency, Washington, D.C.
44. Weiss, S. M., K. Benwell, I. A. Cliffe, R. J. Gillespie, A. R. Knight, J. Lerpiniere, A. Misra, R. M. Pratt, D. Revell, R. Upton, and C. T. Dourish. 2003. Discovery of nonxanthine A2a receptor antagonists for the treatment of Parkinson's disease. Neurology 61:8101-8106.
45. Wongsrichanalai, C., S. Prajakwong, S. R. Meshnick, G. D. Shanks, and K. Thimasarn. 2004. Mefloquine-its 20 years in the Thai Malaria Control Program. Southeast Asian J. Trop. Med. Public Health 35:300-308.
46. World Health Organization. 2005. World malaria report 2005. [Online.] http://www.rbm.who.int/wmr2005. World Health Organization, Geneva, Switzerland.